{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:57:39Z","timestamp":1794009459427,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Micreos Human Health bv"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13063-017-2118-x","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T10:16:25Z","timestamp":1504174585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial)"],"prefix":"10.1186","volume":"18","author":[{"given":"Joan","family":"Tott\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luba","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Pasmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"issue":"14","key":"2118_CR1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","volume":"358","author":"T Bieber","year":"2008","unstructured":"Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483\u201394.","journal-title":"N Engl J Med"},{"issue":"8","key":"2118_CR2","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2006.01047.x","volume":"60","author":"S Lewis-Jones","year":"2006","unstructured":"Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984\u201392.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"2118_CR3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.2004.05776.x","volume":"150","author":"MA Ben-Gashir","year":"2004","unstructured":"Ben-Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are correlated in children with atopic dermatitis. Br J Dermatol. 2004;150(2):284\u201390.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2118_CR4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/bjd.14566","volume":"175","author":"JE Tott\u00e9","year":"2016","unstructured":"Tott\u00e9 JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4):687\u201395.","journal-title":"Br J Dermatol"},{"issue":"5","key":"2118_CR5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1101\/gr.131029.111","volume":"22","author":"HH Kong","year":"2012","unstructured":"Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850\u20139.","journal-title":"Genome Res"},{"issue":"8","key":"2118_CR6","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1038\/jid.2014.122","volume":"134","author":"JB Travers","year":"2014","unstructured":"Travers JB. Toxic interaction between Th2 cytokines and Staphylococcus aureus in atopic dermatitis. J Invest Dermatol. 2014;134(8):2069\u201371.","journal-title":"J Invest Dermatol"},{"key":"2118_CR7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fimmu.2015.00353","volume":"6","author":"T Biedermann","year":"2015","unstructured":"Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T cell immunity in atopic dermatitis by microbes: the yin and yang of cutaneous inflammation. Front Immunol. 2015;6:353.","journal-title":"Front Immunol"},{"issue":"8","key":"2118_CR8","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1468-3083.2012.04635.x","volume":"26","author":"J Ring","year":"2012","unstructured":"Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"2118_CR9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1468-3083.2012.04636.x","volume":"26","author":"J Ring","year":"2012","unstructured":"Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2118_CR10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2133.2010.09743.x","volume":"163","author":"FJ Bath-Hextall","year":"2010","unstructured":"Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010;163(1):12\u201326.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2118_CR11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjd.15139","volume":"177","author":"L Hepburn","year":"2017","unstructured":"Hepburn L, Hijnen DJ, Sellman BR, Mustelin T, Sleeman MA, May RD, Strickland I. The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies. Br J Dermatol. 2017;177(1):63\u201371.","journal-title":"Br J Dermatol"},{"issue":"7","key":"2118_CR12","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/1462-2920.13050","volume":"18","author":"H Brussow","year":"2016","unstructured":"Brussow H. Turning the inside out: the microbiology of atopic dermatitis. Environ Microbiol. 2016;18(7):2089\u2013102.","journal-title":"Environ Microbiol"},{"issue":"11","key":"2118_CR13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/1346-8138.12265","volume":"40","author":"SM Wong","year":"2013","unstructured":"Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. J Dermatol. 2013;40(11):874\u201380.","journal-title":"J Dermatol"},{"issue":"3","key":"2118_CR14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/pde.12150","volume":"30","author":"C Ryan","year":"2013","unstructured":"Ryan C, Shaw RE, Cockerell CJ, Hand S, Ghali FE. Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitis. Pediatr Dermatol. 2013;30(3):308\u201315.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"2118_CR15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/ajd.12371","volume":"57","author":"C Chaptini","year":"2016","unstructured":"Chaptini C, Quinn S, Marshman G. Methicillin-resistant Staphylococcus aureus in children with atopic dermatitis from 1999 to 2014: a longitudinal study. Australas J Dermatol. 2016;57(2):122\u20137.","journal-title":"Australas J Dermatol"},{"issue":"9","key":"2118_CR16","doi-asserted-by":"crossref","first-page":"16135","DOI":"10.1038\/nmicrobiol.2016.135","volume":"1","author":"ID Odell","year":"2016","unstructured":"Odell ID, Flavell RA. Microbiome: ecology of eczema. Nat Microbiol. 2016;1(9):16135.","journal-title":"Nat Microbiol"},{"issue":"4","key":"2118_CR17","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/cid\/cit771","volume":"58","author":"BM Knoll","year":"2014","unstructured":"Knoll BM, Mylonakis E. Antibacterial bioagents based on principles of bacteriophage biology: an overview. Clin Infect Dis. 2014;58(4):528\u201334.","journal-title":"Clin Infect Dis"},{"key":"2118_CR18","unstructured":"Fluit AC, van Marm S, Eichenseher F, Loessner MJ, Pietersma F, Boel CHE. Killing and lysis of Staphylococcus aureus and other staphylococci by an endolysin. 52th ICAAC, abstract F-1516; San Francisco; 2012."},{"key":"2118_CR19","unstructured":"Herpers BL, Badoux P, Pietersma F, Eichenseher F, Loessner MJ. Specific lysis of methicillin susceptible and resistant Staphylococcus aureus by the endolysin Staphefekt SA.100 TM [abstract]. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona; 2014. Abstract R144. https:\/\/www.escmid.org\/escmid_publications\/escmid_elibrary\/?q=2014+herpers&id=2173&L=0&x=0&y=0&tx_solr%5Bfilter%5D%5B0%5D=main_filter_eccmid%253Atrue&tx_solr%5Bfilter%5D%5B1%5D=pub_date%253A201405100000-201405132359 ."},{"key":"2118_CR20","unstructured":"Herpers BL, Badoux P, Tott\u00e9 JEE, Pietersma F, Eichenseher F, Loessner MJ, editors. Specific lysis of Staphylococcus aureus by the bacteriophage endolysin staphefekt SA.100: in vitro studies and human case series. EuroSciCon meeting; Submission for presentation on 5th November 2014; London; 2014. http:\/\/lifescienceevents.com\/wp-content\/uploads\/AntibioticAlternatives5-7thNovABSTRACTS2014.pdf ."},{"key":"2118_CR21","doi-asserted-by":"crossref","unstructured":"Fischetti VA. Lysin therapy for Staphylococcus aureus and other bacterial pathogens. Curr Top Microbiol Immunol. 2016. [Epub ahead of print]","DOI":"10.1007\/82_2015_5005"},{"issue":"Pt 10","key":"2118_CR22","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1099\/jmm.0.061028-0","volume":"62","author":"M Pastagia","year":"2013","unstructured":"Pastagia M, Schuch R, Fischetti VA, Huang DB. Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol. 2013;62(Pt 10):1506\u201316.","journal-title":"J Med Microbiol"},{"issue":"3","key":"2118_CR23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","volume":"131","author":"HC Williams","year":"1994","unstructured":"Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party\u2019s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131(3):383\u201396.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2118_CR24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2133.1994.tb08532.x","volume":"131","author":"HC Williams","year":"1994","unstructured":"Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party\u2019s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131(3):406\u201316.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2118_CR25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2133.1994.tb08531.x","volume":"131","author":"HC Williams","year":"1994","unstructured":"Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. Working Party\u2019s Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol. 1994;131(3):397\u2013405.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2118_CR26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/09546634.2015.1067669","volume":"27","author":"KL Hon","year":"2016","unstructured":"Hon KL, Tsang YC, Lee VW, Pong NH, Ha G, Lee ST, et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate-to-severe eczema: a randomized, placebo-controlled cross-over trial. J Dermatolog Treat. 2016;27(2):156\u201362.","journal-title":"J Dermatolog Treat"},{"key":"2118_CR27","unstructured":"McInnes P, Cutting M. Manual of procedures for Human Microbiome Project, version 12.0. 2010. Available from: http:\/\/www.ncbi.nlm.nih.gov\/projects\/gap\/cgi-bin\/document.cgi?study_id=phs000228.v3.p1&phv=158680&phd=3190&pha=&pht=1184&phvf=&phdf=&phaf=&phtf=&dssp=1&consent=&temp=1#sec64 . Accessed 30 Dec 2016."},{"key":"2118_CR28","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1016\/S0926-9959(98)95291-6","volume":"11","author":"S Tofte","year":"1998","unstructured":"Tofte S, Graeber M, Cherill R, Omoto M, Thurston M, Hanifin J. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol. 1998;11:S197.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2118_CR29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jopan.2009.01.010","volume":"24","author":"HH Jenkins","year":"2009","unstructured":"Jenkins HH, Spencer ED, Weissgerber AJ, Osborne LA, Pellegrini JE. Correlating an 11-point verbal numeric rating scale to a 4-point verbal rating scale in the measurement of pruritus. J Perianesth Nurs. 2009;24(3):152\u20135.","journal-title":"J Perianesth Nurs"},{"issue":"12","key":"2118_CR30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139.","journal-title":"Arch Dermatol"},{"issue":"11","key":"2118_CR31","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","volume":"133","author":"MM Chren","year":"1997","unstructured":"Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433\u201340.","journal-title":"Arch Dermatol"},{"issue":"5","key":"2118_CR32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","volume":"107","author":"MM Chren","year":"1996","unstructured":"Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707\u201313.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2118_CR33","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.2196\/resprot.3418","volume":"3","author":"M Graaf de","year":"2014","unstructured":"de Graaf M, Totte JE, van Os-Medendorp H, van Renselaar W, Breugem CC, Pasmans SG. Treatment of infantile hemangioma in regional hospitals with eHealth support: evaluation of feasibility and acceptance by parents and doctors. JMIR Res Protoc. 2014;3(4):e52.","journal-title":"JMIR Res Protoc"},{"key":"2118_CR34","volume-title":"Linear mixed models for longitudinal data","author":"G Verbeke","year":"2000","unstructured":"Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000."},{"key":"2118_CR35","doi-asserted-by":"crossref","unstructured":"Tott\u00e9 JEE, van Doorn MB, Pasmans SGMA. Successful treatment of chronic Staphylococcus aureus related dermatoses with the topical endolysin Staphefekt SA.100: a report of 3 cases. Case Rep Dermatol. 2017 May 22;9(2):19\u201325","DOI":"10.1159\/000473872"},{"issue":"3","key":"2118_CR36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0625.2000.009003165.x","volume":"9","author":"JD Bos","year":"2000","unstructured":"Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165\u20139.","journal-title":"Exp Dermatol"},{"issue":"1","key":"2118_CR37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1525-1470.2012.01808.x","volume":"30","author":"R Kojima","year":"2013","unstructured":"Kojima R, Fujiwara T, Matsuda A, Narita M, Matsubara O, Nonoyama S, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr Dermatol. 2013;30(1):29\u201335.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"2118_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","volume":"54","author":"UR Hengge","year":"2006","unstructured":"Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1\u201315. quiz 6-8.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2118_CR39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjd.14773","volume":"175","author":"JR Chalmers","year":"2016","unstructured":"Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, von Kobyletzki L, Schmitt J, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema\/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175(1):69\u201379.","journal-title":"Br J Dermatol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:40:01Z","timestamp":1659400801000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2118-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2118-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]},"article-number":"404"}}